StockData
Natera, Inc. logo

Natera, Inc. (NTRA) shareholders

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30138% above fair value
$287.47−1.01 (-0.35%)

Close on Nov 17, 2026Market cap $41.44BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
95.2%
137M of 144M shares
Institutional holders
846
157 new, 66 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 546 sales
Net sold $365.59M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Abigail P. Johnson
Joint filing with FMR LLC (10.50%)
15,131,24510.50%13G (passive) amendmentOct 30, 2026
FMR LLC
Joint filing with Abigail P. Johnson (9.50%)
13,659,5089.50%13G (passive)Sep 30, 2026
JPMorgan Chase & Co.12,825,6409.10%13G (passive) amendmentDec 31, 2025
T. Rowe Price Associates, Inc.9,021,8256.30%13G (passive) amendmentJun 30, 2026
BlackRock, Inc.7,565,9365.60%13G (passive) amendmentMar 31, 2025
Vanguard Capital Management7,205,9395.08%13G (passive)Mar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NTRAValueChange% of portfolio
JPMorgan Chase & Co12,865,3468.93%$3.51B−521,3210.19%
BlackRock, Inc.10,914,6087.57%$2.96B+237,2700.04%
Price T Rowe Associates Inc /Md/9,021,8956.26%$2.45B−3,162,9810.25%
Vanguard Capital Management LLC6,228,2164.32%$1.69B+219,7200.04%
Vanguard Portfolio Management LLC5,782,6404.01%$1.57B+137,9450.07%
FMR LLC5,451,3963.78%$1.48B+2,897,1420.06%
Wellington Management Group Llp4,040,7382.80%$1.10B−727,8550.19%
State Street Corp3,655,6182.54%$992.32M+238,1460.03%
Duquesne Family Office LLC3,186,3062.21%$864.92M+122,70016.60%
Geode Capital Management, LLC2,750,0131.91%$744.57M−25,9150.04%
Franklin Resources Inc2,725,9031.89%$739.95M+240,5780.16%
Castle Hook Partners LP2,596,2761.80%$704.76M+66,4663.23%
Coatue Management LLC2,505,0901.74%$680.01M−36,7521.40%
Aqr Capital Management LLC2,344,5701.63%$628.09M+70,5790.22%
Farallon Capital Management LLC2,218,3661.54%$602.18M−989,0002.78%
Massachusetts Financial Services Co /Ma/1,971,3911.37%$535.08M−68,7150.17%
Norges Bank1,828,1221.27%$496.24MNew0.05%
Fred Alger Management, LLC1,778,0091.23%$482.64M+21,5371.61%
Goldman Sachs Group Inc1,720,1521.19%$466.94M+952,9210.04%
Sofinnova Investments, Inc.1,550,2801.08%$420.82M–21.76%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026846137M95.2%157 / 356242 / 6615M12M
Q1 2026766134M93.2%98 / 301265 / 10623M9M
Q4 2025785133M92.5%185 / 277241 / 6316M24M
Q3 2025686142M98.5%111 / 269230 / 6522M11M
Q2 2025648132M91.5%110 / 272197 / 5516M14M
Q1 2025597130M90.4%116 / 238192 / 10318M12M
Q4 2024596125M86.7%146 / 185211 / 3715M16M
Q3 2024495126M87.6%68 / 180195 / 4221M17M
Q2 2024475129M89.4%96 / 184147 / 2915M16M
Q1 2024411131M90.7%96 / 145135 / 3420M13M
Q4 2023351124M86.0%67 / 129127 / 3223M14M
Q3 2023319115M79.6%43 / 113120 / 3814M8M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

686 funds held NTRA in Q2 2026, 33% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of NTRAValue% of fundAs of
JPMorgan Large Cap Growth Fund5,550,9403.85%$1.51B1.24%Jun 30, 2026
Vanguard Total Stock Market Index Fund4,320,3513.00%$1.17B0.05%Jun 30, 2026
Vanguard Small-Cap Index Fund3,119,4162.16%$846.77M0.45%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund1,799,3591.25%$488.44M1.04%Jun 30, 2026
Vanguard Extended Market Index Fund1,642,2711.14%$445.79M0.46%Jun 30, 2026
Fidelity Contrafund1,617,2221.12%$438.99M0.24%Jun 30, 2026
Franklin Dynatech Fund1,450,0001.01%$393.60M1.30%Jun 30, 2026
MFS Mid Cap Growth Fund1,345,5720.93%$300.56M2.18%May 31, 2026
Growth Fund of America988,7240.69%$220.85M0.06%May 31, 2026
iShares Biotechnology ETF967,6830.67%$262.68M2.89%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.817,7750.57%$221.99M1.51%Jun 30, 2026
iShares Russell Mid-Cap Growth ETF805,8930.56%$218.76M1.01%Jun 30, 2026
T. Rowe Price Large-Cap Growth Fund800,4990.56%$217.30M1.06%Jun 30, 2026
Vanguard U.S. Growth Fund783,6200.54%$175.04M0.37%May 31, 2026
JPMorgan Mid Cap Growth Fund781,5560.54%$212.15M1.60%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Matthew RabinowitzEXECUTIVE CHAIRMAN, Director2,116,9281.47%Nov 4, 2026
Steven Leonard ChapmanCEO AND PRESIDENT, Director87,4310.06%Nov 4, 2026
Daniel RabinowitzSEC. AND CHIEF LEGAL OFFICER167,8800.12%Nov 4, 2026
John FeskoPRESIDENT, CHIEF BUS. OFFICER195,2760.14%Nov 4, 2026
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS101,3230.07%Nov 4, 2026
Michael Burkes BrophyCHIEF FINANCIAL OFFICER45,7790.03%Nov 4, 2026
Jonathan SheenaDirector229,4620.16%Nov 13, 2026
Rowan E. ChapmanDirector4,6630.00%Jul 17, 2026
Eric H. RubinDirector2,2040.00%Jun 30, 2026
Roelof BothaDirector1,080,6630.75%Jun 30, 2026
Roy D. BaynesDirector20,0830.01%Jun 30, 2026
Thomas J. Lynch Jr.Director1,9050.00%Jun 30, 2026
Herm RosenmanDirector5,8210.00%Jun 30, 2026
Gail Boxer MarcusDirector7,8520.01%Jun 30, 2026
Monica BertagnolliDirector6,9450.00%Jun 30, 2026
Brinkley Ruth WilliamsDirector5,4750.00%Apr 28, 2026
James HealyDirector1,596,5401.11%Apr 29, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−40$324.76$12.99K7,500
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−80$322.88$25.83K7,540
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−120$320.07$38.41K7,620
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−240$319.22$76.61K7,740
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−182$317.96$57.87K7,980
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−48$317.33$15.23K8,162
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−40$315.28$12.61K8,210
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−40$323.06$12.92K7,500
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−40$322.00$12.88K7,540
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−160$320.02$51.20K7,580
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−240$319.77$76.75K7,740
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−145$317.87$46.09K7,980
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−85$316.93$26.94K8,125
Jonathan Sheena
Director
Nov 11, 2026Sale(10b5-1 plan)−40$315.26$12.61K8,210
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−45$325.05$14.63K214,462
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−40$323.86$12.95K214,507
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−16$321.85$5.15K214,547
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−51$321.12$16.38K214,563
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−131$320.07$41.93K214,614
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−105$319.30$33.53K214,745
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−56$318.17$17.82K214,850
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−1,838$316.87$582.40K214,906
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−169$315.48$53.32K216,744
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−108$314.71$33.99K216,913
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−74$313.32$23.19K217,021
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−106$312.20$33.09K217,095
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−100$311.31$31.13K217,201
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−110$310.17$34.12K217,301
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−64$309.08$19.78K217,411
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−50$308.20$15.41K217,475
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−21$306.46$6.44K217,525
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−51$305.75$15.59K217,546
Jonathan Sheena
Director
Nov 6, 2026Sale(10b5-1 plan)−15$304.57$4.57K217,597
Michael Burkes Brophy
CHIEF FINANCIAL OFFICER
Nov 3, 2026Sale(10b5-1 plan)−470$391.49$184.00K45,779
John Fesko
PRESIDENT, CHIEF BUS. OFFICER
Nov 2, 2026Sale(10b5-1 plan)−295$400.29$118.09K195,276
John Fesko
PRESIDENT, CHIEF BUS. OFFICER
Nov 2, 2026Sale(10b5-1 plan)−7$388.20$2.72K195,571
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−240$416.45$99.95K101,323
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−760$415.52$315.79K101,563
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−80$414.16$33.13K102,323
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−120$412.88$49.55K102,403
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−120$411.73$49.41K102,523
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−120$410.71$49.29K102,643
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−520$409.46$212.92K102,763
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−408$408.08$166.50K103,283
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−432$406.94$175.80K103,691
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−200$405.26$81.05K104,123
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−410$400.29$164.12K104,323
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Nov 2, 2026Sale(10b5-1 plan)−9$388.20$3.49K104,733
Daniel Rabinowitz
SEC. AND CHIEF LEGAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−334$400.29$133.70K167,880
Daniel Rabinowitz
SEC. AND CHIEF LEGAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−7$388.20$2.72K168,214
Steven Leonard Chapman
CEO AND PRESIDENT, Director
Nov 2, 2026Sale(10b5-1 plan)−2,866$415.64$1.19M87,431
Steven Leonard Chapman
CEO AND PRESIDENT, Director
Nov 2, 2026Sale(10b5-1 plan)−914$400.29$365.87K90,297
Steven Leonard Chapman
CEO AND PRESIDENT, Director
Nov 2, 2026Sale(10b5-1 plan)−21$387.90$8.15K91,211
Michael Burkes Brophy
CHIEF FINANCIAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−317$400.29$126.89K46,249
Michael Burkes Brophy
CHIEF FINANCIAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−8$388.03$3.10K46,566
Jonathan Sheena
Director
Nov 2, 2026Sale(10b5-1 plan)−109$400.29$43.63K217,574
Jonathan Sheena
Director
Nov 2, 2026Sale(10b5-1 plan)−3$388.20$1.16K217,683
Matthew Rabinowitz
EXECUTIVE CHAIRMAN, Director
Nov 2, 2026Sale(10b5-1 plan)−731$400.29$292.62K2,116,928
Matthew Rabinowitz
EXECUTIVE CHAIRMAN, Director
Nov 2, 2026Sale(10b5-1 plan)−17$388.20$6.60K2,117,659
Michael Burkes Brophy
CHIEF FINANCIAL OFFICER
Oct 30, 2026Sale(10b5-1 plan)−1,906$425.55$811.10K46,574

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
4.39%
6M shares short
Days to cover
4.2
At 1M shares a day
Change since last report
+3.8%
From 6M shares
Short volume, 20 days
44.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Natera's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,972 shares on Aug 24, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Michael Burkes Brophy
Officer
Nov 3, 2026470$178.09KNov 3, 2026Restricted Stock Units
Steven Leonard Chapman
Officer, Director
Nov 2, 20262,866$1.19MNov 2, 2026Restricted Stock
Jonathan Sheena
DIRECTOR
Nov 2, 2026108$44.74KNov 2, 2026Restricted Stock Units
Matthew Rabinowitz
DIRECTOR
Nov 2, 2026722$299.12KNov 2, 2026Restricted Stock Units
Daniel Rabinowitz
OFFICER
Nov 2, 2026330$136.72KNov 2, 2026Restricted Stock Units
Solomon Moshkevich
OFFICER
Nov 2, 2026405$167.79KNov 2, 2026Restricted Stock Units
John Fesko
OFFICER
Nov 2, 2026291$120.56KNov 2, 2026Restricted Stock Units
Steven Leonard Chapman
OFFICER, DIRECTOR
Nov 2, 2026903$374.11KNov 2, 2026Restricted Stock Units
Michael Burkes Brophy
OFFICER
Nov 2, 2026313$129.68KNov 2, 2026Restricted Stock Units
Solomon Moshkevich
Officer
Nov 2, 20263,000$1.23MNov 2, 2026Restricted Stock
Michael Burkes Brophy
Officer
Oct 30, 20261,906$831.02KOct 30, 2026Restricted Stock Units
Michael Burkes Brophy
Officer
Oct 28, 20261,178$483.95KOct 28, 2026Restricted Stock Units
Jonathan Sheena
DIRECTOR
Oct 28, 2026191$78.47KOct 28, 2026Restricted Stock Units
Daniel Rabinowitz
OFFICER
Oct 28, 2026988$405.89KOct 28, 2026Restricted Stock Units
Solomon Moshkevich
OFFICER
Oct 28, 20261,185$486.82KOct 28, 2026Restricted Stock Units

Congress trades

6 trades in Natera reported by 2 members of the House

MemberTypeTradedAmountFiled
Josh Gottheimer
NJ05 · joint account
BoughtSep 22, 2025$1K–15KOct 15, 2025
Josh Gottheimer
NJ05 · joint account
BoughtAug 22, 2025$1K–15KSep 5, 2025
Josh Gottheimer
NJ05 · joint account
Sold (part)Jul 22, 2025$1K–15KAug 11, 2025
Josh Gottheimer
NJ05 · joint account
BoughtNov 20, 2024$1K–15KDec 5, 2024
Daniel Goldman
NY10
Sold (part)Apr 10, 2023$1K–15KMay 19, 2023
Daniel Goldman
NY10
BoughtMar 6, 2023$1K–15KApr 17, 2023

See a number that looks wrong?